Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib

Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

“…11 By contrast, EGFR inhibitors may be effective for mucinous urethral adenocarcinoma. Bryce et al 4 reported a case in which multiple-gene panel testing revealed strong amplification and immunostaining of EGFR, contributing to successful treatment with erlotinib. In this case as well, EGFR immunostaining was strongly positive for mucinous urethral adenocarcinoma (Fig.…”

“…Urethroscopy may show space‐occupying lesions in the prostatic urethra and T2‐weighted MRI may show hyperintense signals in the prostate 2 . The prevalence of urethral adenocarcinoma in Europe is estimated at 0.1 per 1 million, 3 and only about 20 cases of mucinous urethral adenocarcinoma have been reported to date worldwide 4 . Because of its rarity, there are few reports of systemic treatment other than chemotherapy for mucinous urethral adenocarcinoma.…”

Editorial Comment to Systemic treatment for coexisting mucinous urethral adenocarcinoma and prostate adenocarcinoma

“…Bryce et al reported a case of mucinous urethral adenocarcinoma in which targetable EGFR amplification led to successful treatment with erlotinib. 2 Before erlotinib, the patient received both traditional bladder cancer and colon cancer regimens. However, the bladder cancer regimen led to only a brief response with severe side effects, and the colon cancer regimen had similar toxicity.…”

“…Bryce et al . reported a case of mucinous urethral adenocarcinoma in which targetable EGFR amplification led to successful treatment with erlotinib 2 . Before erlotinib, the patient received both traditional bladder cancer and colon cancer regimens.…”